NCT04330729Recruiting
The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp
The Effect of Low-dose Salicylate Treatment on Platelet Function in Patients With Renal Failure Treated With Darbepoetin Alfa
Source: ClinicalTrials.gov · Last updated 25 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of the study is to 1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2. To determine whether salicylate treatment changes the effect of EPO (erythropoietin) on platelet function.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 20 Mar 2020
- Start date
- 15 Apr 2020
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Zealand University Hospital
- Diseases
- Chronic kidney disease
- NCT number
- NCT04330729
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 15 Apr 2020 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known indication for ASA. If the patient is being treated with ASA, and the physician does not find any indication for this treatment, this can be stopped, and the patient included after 4 weeks.
- Current anticoagulant therapy, e.g. warfarin, ADP receptor inhibitor (excepting short-term anticoagulant therapy in connection with dialysis)
- Change in ESA dosis \>33,3% within previous 2 month
Other illness
- Known allergy to ASA
- Known contraindication to ASA, e.g. recent bleeding episode.
- Active cancer - except for non-melanoma skin-cancer
Lab values
- Raised reticulocyte count
Age
- Fertile women. Pregnancy is excessively rare in dialysis patients. Women who are \<50 years, or who are still menstruating will be excluded from the study.
Other
- Short expected length of life
- Inability to give informed consent
- Expected non-compliance
- Iron deficiency (defined as a reticulocyte Hgb \<1,8 fmol. Patients can be included when their iron deficiency has been cured. .
- Stable Aranesp ® dose \<20 µg/week.
Who the study is looking for
- Chronic hemodialysis, peritoneal dialysis or CKD 5 treated conservatively
- aged 18-85
- indication for treatment with Erythropoiesis-stimulating agents (ESA)
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medicinsk afdeling, SUH Roskilde Coordinator of this site? Confirm its status | Roskilde | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.